Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae | Zendy

Yoshikuni Onodera | Zendy; Yoko Uchida | Zendy; Mayumi Tanaka | Zendy; Kenichi Sato | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae

Author(s) -

Yoshikuni Onodera,

Yoko Uchida,

Mayumi Tanaka,

Kenichi Sato

Publication year - 1999

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/44.4.533

Subject(s) - dna gyrase , sparfloxacin , topoisomerase iv , streptococcus pneumoniae , microbiology and biotechnology , levofloxacin , ofloxacin , ciprofloxacin , antibacterial agent , topoisomerase , minimum inhibitory concentration , chemistry , biology , dna , antibiotics , escherichia coli , biochemistry , gene

The in-vitro inhibitory activities of sitafloxacin (DU-6859a) and other quinolones against Streptococcus pneumoniae DNA gyrase and topoisomerase IV were measured. IC50s of levofloxacin, ciprofloxacin, sparfloxacin and tosufloxacin against DNA gyrase were almost three to 12 times higher than those against topoisomerase IV. On the other hand, sitafloxacin showed dual inhibitory activity against both enzymes and its IC50s were the lowest among those of the quinolones tested. These results suggest that sitafloxacin is an effective agent against pneumococcal infections and that the incidence of drug-resistant mutants is low.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research